Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 14
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Mechanisms of bacterial membrane permeabilization by crotalicidin (Ctn) and its fragment Ctn(15–34), antimicrobial peptides from rattlesnake venom

  • Pérez-Peinado, Clara, 1991-
  • Almeida Dias, Susana
  • Domingues, Marco M.
  • Benfield, Aurélie H.
  • Miguel Freire, João
  • Rádis-Baptista, Gandhi
  • Gaspar, Diana
  • Castanho, Miguel A.R.B.
  • Craik, David J.
  • Troeira Henriques, Sónia
  • Salomé Veiga, Ana
  • Andreu Martínez, David
Crotalicidin (Ctn), a cathelicidin-related peptide from the venom of a South American rattlesnake, possesses potent antimicrobial, antitumor, and antifungal properties. Previously, we have shown that its C-terminal fragment, Ctn(15-34), retains the antimicrobial and antitumor activities but is less toxic to healthy cells and has improved serum stability. Here, we investigated the mechanisms of action of Ctn and Ctn(15-34) against Gram-negative bacteria. Both peptides were bactericidal, killing ∼90% of Escherichia coli and Pseudomonas aeruginosa cells within 90-120 and 5-30 min, respectively. Studies of ζ potential at the bacterial cell membrane suggested that both peptides accumulate at and neutralize negative charges on the bacterial surface. Flow cytometry experiments confirmed that both peptides permeabilize the bacterial cell membrane but suggested slightly different mechanisms of action. Ctn(15-34) permeabilized the membrane immediately upon addition to the cells, whereas Ctn had a lag phase before inducing membrane damage and exhibited more complex cell-killing activity, probably because of two different modes of membrane permeabilization. Using surface plasmon resonance and leakage assays with model vesicles, we confirmed that Ctn(15-34) binds to and disrupts lipid membranes and also observed that Ctn(15-34) has a preference for vesicles that mimic bacterial or tumor cell membranes. Atomic force microscopy visualized the effect of these peptides on bacterial cells, and confocal microscopy confirmed their localization on the bacterial surface. Our studies shed light onto the antimicrobial mechanisms of Ctn and Ctn(15-34), suggesting Ctn(15-34) as a promising lead for development as an antibacterial/antitumor agent., This work was supported by Spanish Ministry of Economy and Competitiveness (MINECO) Grants SAF2011-24899 and AGL2014-52395-C2, by Fundação para a Ciência e a Tecnologia (FCT, Portugal) Grants PTDC/QEQ-MED/4412/2014, and by EU Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE) program Grant 644167, 2015–2019. The authors declare that they have no conflicts of interest with the contents of this article.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

New Potent Membrane-Targeting Antibacterial Peptides from Viral Capsid Proteins

  • Dias, Susana A.
  • Miguel Freire, João
  • Pérez-Peinado, Clara, 1991-
  • Domingues, Marco M.
  • Gaspar, Diana
  • Vale, Nuno
  • Gomes, Paula
  • Andreu Martínez, David
  • Henriques, Sónia T.
  • Castanho, Miguel A.R.B.
  • Veiga, Ana Salomé
The increasing prevalence of multidrug-resistant bacteria urges the development of new antibacterial agents. With a broad spectrum activity, antimicrobial peptides have been considered potential antibacterial drug leads. Using bioinformatic tools we have previously shown that viral structural proteins are a rich source for new bioactive peptide sequences, namely antimicrobial and cell-penetrating peptides. Here, we test the efficacy and mechanism of action of the most promising peptides among those previously identified against both Gram-positive and Gram-negative bacteria. Two cell-penetrating peptides, vCPP 0769 and vCPP 2319, have high antibacterial activity against Staphylococcus aureus, MRSA, Escherichia coli, and Pseudomonas aeruginosa, being thus multifunctional. The antibacterial mechanism of action of the two most active viral protein-derived peptides, vAMP 059 and vCPP 2319, was studied in detail. Both peptides act on both Gram-positive S. aureus and Gram-negative P. aeruginosa, with bacterial cell death occurring within minutes. Also, these peptides cause bacterial membrane permeabilization and damage of the bacterial envelope of P. aeruginosa cells. Overall, the results show that structural viral proteins are an abundant source for membrane-active peptides sequences with strong antibacterial properties., This work was supported by Fundação para a Ciência e a Tecnologia (FCT-MCTES, Portugal) projects PTDC/QEQ-MED/4412/2014 and UID/QUI/50006/2013, and by Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE): call H2020-MSCA-RISE-2014, Grant agreement 644167, 2015–2019. SD, JF, and DG acknowledge FCT for fellowships PD/BD/114425/2016, SFRH/BD/70423/2010, and SFRH/BPD/109010/2015, respectively, and MD for a grant (PTDC/BBB-BQB/3494/2014). ASV and NV acknowledge FCT for funding within the FCT Investigator Programme, IF/00803/2012 and IF/00092/2014, respectively. CP-P acknowledges financial support from the Spanish Ministry of Economy and Competitiveness, through grant AGL2014-52395-C2-2-R and the “María de Maeztu” Programme for Units of Excellence in R&D (MDM-2014-0370). PG acknowledges “Comissão de Coordenação e Desenvolvimento Regional do Norte (CCDR-N)/NORTE2020/Portugal 2020” for funding through project DESignBIOtechHealth (ref. Norte-01-0145-FEDER-000024). SH is the recipient of an Australian Research Council Future Fellowship (FT150100398).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Decoding the human serum interactome of snake-derived antimicrobial peptide Ctn[15-34]: Toward an explanation for unusually long half-life

  • Pérez-Peinado, Clara, 1991-
  • Defaus, Sira
  • Sans-Comerma, Laura
  • Valle, Javier
  • Andreu Martínez, David
The inherent propensity to enzymatic degradation of most peptides remains a bottleneck in their therapeutic development. Efficient, early screening methods are necessary for in vitro characterization of the molecular events occurring when peptides get in contact with biological fluids such us plasma. Herein we present an affinity purification/MS approach for mapping peptide serum interactors. We have applied this methodology to identify the serum partners of antibiotic peptide Ctn [15-34], aiming to ascertain the molecular interactions underlying its unusually long half-life (~ 12 h) in human serum. From 42 proteins captured in pull-downs with biotinylated Ctn [15-34] as bait, five are of special interest for their transport/binding properties hence alleged peptide arresting potential. The subset contains two members of the albumin superfamily, two apolipoproteins and a globulin. All five share a binding ability for hydrophobic species, and also bind Ctn [15-34], presumably via its C-terminal hydrophobic section, with affinities in the μM range as shown by surface plasmon resonance. Additionally, our functional enrichment reveals several significant immune-related processes suggesting an immunomodulatory role of Ctn [15-34]. Taken together, this study exemplifies how pharmacoproteomics can be used to analyze bioavailability issues and shed light on the serum interactors ultimately conferring protection to Ctn [15-34] against proteolytic events. SIGNIFICANCE: The affinity purification/MS identification methodology reported here can be viewed as a routine pharmacoproteomic approach to investigate the serum interactome of peptide drugs, identifying proteins affecting bioavailability and thus assisting the peptide drug development process. The specific results described here enlighten the serum stability issues of peptide Ctn [15-34] and ratify its promising future as an anti-infective lead., The proteomic analyses were performed at the CRG/UPF Proteomics Unit, which is part of the of Proteored, PRB3 and is supported by grant PT17/0019, of the PE I+D+i 2013-2016, funded by ISCIII and ERDF. This work was supported the Spanish Ministry of Economy and Competitiveness (MINECO) [grant numbers SAF2011-24899 and AGL2014-52395-C2] and by the EU Marie Sklodowska-Curie Research and Innovation Staff Exchange (RISE) program [grant number 644167, 2015-2019]. CP-P acknowledges the MINECO "María de Maeztu" Program for Units of Excellence in R&D (MDM-2014-0370) for a predoctoral fellowship.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

1988-2018: Thirty years of drug smuggling at the nano scale. Challenges and opportunities of cell-penetrating peptides in biomedical research

  • Gallo, María, 1989-
  • Defaus, Sira
  • Andreu Martínez, David
In 1988, two unrelated papers reported the discovery of peptide vectors with innate cell translocation properties, setting the ground for a new area of research that over the years has grown into considerable therapeutic potential. The vectors, named cell-penetrating peptides (CPPs), constitute a now large and diversified family, sharing the extraordinary ability to diffuse unaltered across cell membranes while ferrying diverse associated cargos. Such properties have made CPPs ideal tools for delivery of nucleic acids, proteins and other therapeutic/diagnostic molecules to cells and tissues via covalent conjugation or complexation. This year 2018 marks the 30th anniversary of a peptide research landmark opening new perspectives in drug delivery. Given its vastness, exhaustive coverage of the main features and accomplishments in the CPP field is virtually impossible. Hence this manuscript, after saluting the above 30th jubilee, focuses by necessity on the most recent contributions, providing a comprehensive list of recognized CPPs and their latest-reported applications over the last two years. In addition, it thoroughly reviews three areas of peptide vector research of particular interest to us, namely (i) efficient transport of low-bioavailability drugs into the brain; (ii) CPP-delivered disruptors of G protein-coupled receptor (GPCRs) heteromers related to several disorders, and (iii) CPP-mediated delivery of useful but poorly internalized drugs into parasites., Work supported by the Spanish Ministry of Economy and Competitiveness (MINECO), grants SAF2011-24899 and AGL2014-52395-C2 (to D.A.) and “María de Maeztu” Program for Units of Excellence in R&D (to Pompeu Fabra University). Additional support from the EU Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE) grant 644167, 2015–2019 (D.A. & S.D.).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

vCPP2319 interacts with metastatic breast cancer extracellular vesicles (EVs) and transposes a human blood-brain barrier model

  • Oliveira, Filipa D.
  • Cavaco, Marco
  • Figueira, Tiago N.
  • Napoleão, Patrícia
  • Valle, Javier
  • Neves, Vera
  • Andreu Martínez, David
  • Castanho, Miguel A.R.B.
Brain metastases (BM) are frequently found in cancer patients and, though their precise incidence is difficult to estimate, there is evidence for a correlation between BM and specific primary cancers, such as lung, breast, and skin (melanoma). Among all these, breast cancer is the most frequently diagnosed among women and, in this case, BM cause a critical reduction of the overall survival (OS), especially in triple negative breast cancer (TNBC) patients. The main challenge of BM treatment is the impermeable nature of the blood-brain barrier (BBB), which shields the central nervous systems (CNS) from chemotherapeutic drugs. Extracellular vesicles (EVs) have been proposed as ideal natural drug carriers and these may exhibit some advantages over synthetic nanoparticles (NPs). In this work, we isolate breast cancer-derived EVs and study their ability to carry vCPP2319, a peptide with dual cell-penetration and anticancer activities. The selective cytotoxicity of anticancer peptide-loaded EVs towards breast cancer cells and their ability to translocate an in vitro BBB model are also addressed. Overall, it was possible to conclude that vCPP2319 naturally interacts with breast cancer-derived EVs, being retained at the surface of these vesicles. Moreover, the results revealed a cytotoxic activity for peptide-loaded EVs similar to that obtained with the peptide alone and the ability of peptide-loaded EVs to translocate an in vitro BBB model, which contrasts with the results obtained with the peptide alone. In conclusion, this work supports the use of EVs in the development of biological drug-delivery systems (DDS) capable of translocating the BBB., FDO and MC acknowledge FCT I.P. for fellowships PD/BD/135046/2017, PD/BD/128281/2017. FCT I.P. is also acknowledged for funding (Projects PTDC/BIA-BQM/5027/2020 and PTDC/BTM-MAT/2472/2021). Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE) is also acknowledged for funding: call H2020-MSCA-RISE-2014, grant agreement 644167, 2015–2019. The project leading to these results have received funding from “la Caixa” Foundation (ID 100010434) and FCT, I.P under the agreement LCF/PR/HP21/52310015. Work at UPF was supported by grant AGL2017-84097-C2-2-R and the “María de Maeztu” Program for Units of Excellence in R&D (MDM-2014-0370) from the Spanish Ministry of Economy and Competitiveness (MINECO).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The antimetastatic breast cancer activity of the viral protein-derived peptide vCPP2319 as revealed by cellular biomechanics

  • Oliveira, Filipa D.
  • Cavaco, Marco
  • Figueira, Tiago N.
  • Valle, Javier
  • Neves, Vera
  • Andreu Martínez, David
  • Gaspar, Diana
  • Castanho, Miguel A.R.B.
The incidence of metastatic breast cancer (MBC) is increasing and the therapeutic arsenal available to fight it is insufficient. Brain metastases, in particular, represent a major challenge for chemotherapy as the impermeable nature of the blood-brain barrier (BBB) prevents most drugs from targeting cells in the brain. For their ability to transpose biological membranes and transport a broad spectrum of bioactive cargoes, cell-penetrating peptides (CPPs) have been hailed as ideal candidates to deliver drugs across biological barriers. A more ambitious approach is to have the CPP as a drug itself, capable of both killing cancer cells and interacting with the blood/brain interface, therefore blocking the onset of brain metastases. vCPP2319, a viral protein-derived CPP, has both properties as it: (a) is selective toward human breast cancer cells (MDA-MB-231) and increases cell stiffness compared to breast epithelial cells (MCF 10A) hindering the progression of metastases; and (b) adsorbs at the surface of human brain endothelial cells potentially counteracting metastatic cells from reaching the brain. Overall, the results reveal the selective anticancer activity of the peptide vCPP2319, which is also able to reside at the blood-brain interface, therefore counteracting brain penetration by metastatic cancer cells., FDO, MC, and DG acknowledge FCT I.P. for fellowships PD/BD/135046/2017, PD/BD/128281/2017, and SFRH/ BPD/73500/2010. FCT I.P. is also acknowledged for funding (Projects PTDC/BIA-BQM/5027/2020 and PTDC/BBB-NAN/1578/2014). Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE) is also acknowledged for funding: call H2020-MSCA-RISE-2014, grant agreement 644167, 2015–2019. Work at UPF was supported by grant AGL2017-84097-C2-2-R and the “María de Maeztu” Program for Units of Excellence in R&D (MDM-2014-0370) from the Spanish Ministry of Economy and Competitiveness (MINECO).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The mechanism of action of pepR, a viral-derived peptide, against Staphylococcus aureus biofilms

  • Pinto, Sandra N.
  • Dias, Susana A.
  • Cruz, Ana F.
  • Mil-Homens, Dalila
  • Fernandes, Fabio
  • Valle, Javier
  • Andreu Martínez, David
  • Prieto, Manuel
  • Castanho, Miguel A.R.B.
  • Coutinho, Ana
  • Salomé Veiga, Ana
Objectives: To investigate the mechanism of action at the molecular level of pepR, a multifunctional peptide derived from the Dengue virus capsid protein, against Staphylococcus aureus biofilms. Methods: Biofilm mass, metabolic activity and viability were quantified using conventional microbiology techniques, while fluorescence imaging methods, including a real-time calcein release assay, were employed to investigate the kinetics of pepR activity at different biofilm depths. Results: Using flow cytometry-based assays, we showed that pepR is able to prevent staphylococcal biofilm formation due to a fast killing of planktonic bacteria, which in turn resulted from a peptide-induced increase in the permeability of the bacterial membranes. The activity of pepR against pre-formed biofilms was evaluated through the application of a quantitative live/dead confocal laser scanning microscopy (CLSM) assay. The results show that the bactericidal activity of pepR on pre-formed biofilms is dose and depth dependent. A CLSM-based assay of calcein release from biofilm-embedded bacteria was further developed to indirectly assess the diffusion and membrane permeabilization properties of pepR throughout the biofilm. A slower diffusion and delayed activity of the peptide at deeper layers of the biofilm were quantified. Conclusions: Overall, our results show that the activity of pepR on pre-formed biofilms is controlled by its diffusion along the biofilm layers, an effect that can be counteracted by an additional administration of peptide. Our study sheds new light on the antibiofilm mechanism of action of antimicrobial peptides, particularly the importance of their diffusion properties through the biofilm matrix on their activity., This work was supported by the Fundação para a Ciência e a Tecnologia (FCT)/Ministério da Ciência, Tecnologia e Ensino Superior (MCTES) (projects PTDC/QEQ-MED/4412/2014, FAPESP/20107/2014, SAICTPAC/0019/2015, PPBI-POCI-01-0145-FEDER-022122); by the Spanish Ministry of Economy and Competitiveness (MINECO) (grant AGL2014-5239-C2-2R); and by the Marie Skłodowska-Curie Research and Innovation Staff Exchange (grant H2020-MSCA-RISE-2014–644167). We also acknowledge project UID/BIM/50005/2019, funded by FCT/MCTES through Fundos do Orçamento de Estado. S. N. P., S. A. D., A. F. C. and D. M.-H. are the recipients of fellowships from the FCT (SFRH/BPD/92409/2013, PD/BD/114425/2016, PD/BD/136866/2018 and SFRH/BPD/91831/2012, respectively). A. S. V. and F. F. are FCT Researchers (IF/00803/2012 and IF/00386/2015, respectively).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The antimetastatic breast cancer activity of the viral protein-derived peptide vCPP2319 as revealed by cellular biomechanics

  • Oliveira, Filipa D.
  • Cavaco, Marco
  • Figueira, Tiago N.
  • Valle, Javier
  • Neves, Vera
  • Andreu Martínez, David
  • Gaspar, Diana
  • Castanho, Miguel A.R.B.
The incidence of metastatic breast cancer (MBC) is increasing and the therapeutic arsenal available to fight it is insufficient. Brain metastases, in particular, represent a major challenge for chemotherapy as the impermeable nature of the blood-brain barrier (BBB) prevents most drugs from targeting cells in the brain. For their ability to transpose biological membranes and transport a broad spectrum of bioactive cargoes, cell-penetrating peptides (CPPs) have been hailed as ideal candidates to deliver drugs across biological barriers. A more ambitious approach is to have the CPP as a drug itself, capable of both killing cancer cells and interacting with the blood/brain interface, therefore blocking the onset of brain metastases. vCPP2319, a viral protein-derived CPP, has both properties as it: (a) is selective toward human breast cancer cells (MDA-MB-231) and increases cell stiffness compared to breast epithelial cells (MCF 10A) hindering the progression of metastases; and (b) adsorbs at the surface of human brain endothelial cells potentially counteracting metastatic cells from reaching the brain. Overall, the results reveal the selective anticancer activity of the peptide vCPP2319, which is also able to reside at the blood-brain interface, therefore counteracting brain penetration by metastatic cancer cells., FDO, MC, and DG acknowledge FCT I.P. for fellowships PD/BD/135046/2017, PD/BD/128281/2017, and SFRH/ BPD/73500/2010. FCT I.P. is also acknowledged for funding (Projects PTDC/BIA-BQM/5027/2020 and PTDC/BBB-NAN/1578/2014). Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE) is also acknowledged for funding: call H2020-MSCA-RISE-2014, grant agreement 644167, 2015–2019. Work at UPF was supported by grant AGL2017-84097-C2-2-R and the “María de Maeztu” Program for Units of Excellence in R&D (MDM-2014-0370) from the Spanish Ministry of Economy and Competitiveness (MINECO).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

New Potent Membrane-Targeting Antibacterial Peptides from Viral Capsid Proteins

  • Dias, Susana A.
  • Miguel Freire, João
  • Pérez-Peinado, Clara, 1991-
  • Domingues, Marco M.
  • Gaspar, Diana
  • Vale, Nuno
  • Gomes, Paula
  • Andreu Martínez, David
  • Henriques, Sónia T.
  • Castanho, Miguel A.R.B.
  • Veiga, Ana Salomé
The increasing prevalence of multidrug-resistant bacteria urges the development of new antibacterial agents. With a broad spectrum activity, antimicrobial peptides have been considered potential antibacterial drug leads. Using bioinformatic tools we have previously shown that viral structural proteins are a rich source for new bioactive peptide sequences, namely antimicrobial and cell-penetrating peptides. Here, we test the efficacy and mechanism of action of the most promising peptides among those previously identified against both Gram-positive and Gram-negative bacteria. Two cell-penetrating peptides, vCPP 0769 and vCPP 2319, have high antibacterial activity against Staphylococcus aureus, MRSA, Escherichia coli, and Pseudomonas aeruginosa, being thus multifunctional. The antibacterial mechanism of action of the two most active viral protein-derived peptides, vAMP 059 and vCPP 2319, was studied in detail. Both peptides act on both Gram-positive S. aureus and Gram-negative P. aeruginosa, with bacterial cell death occurring within minutes. Also, these peptides cause bacterial membrane permeabilization and damage of the bacterial envelope of P. aeruginosa cells. Overall, the results show that structural viral proteins are an abundant source for membrane-active peptides sequences with strong antibacterial properties., This work was supported by Fundação para a Ciência e a Tecnologia (FCT-MCTES, Portugal) projects PTDC/QEQ-MED/4412/2014 and UID/QUI/50006/2013, and by Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE): call H2020-MSCA-RISE-2014, Grant agreement 644167, 2015–2019. SD, JF, and DG acknowledge FCT for fellowships PD/BD/114425/2016, SFRH/BD/70423/2010, and SFRH/BPD/109010/2015, respectively, and MD for a grant (PTDC/BBB-BQB/3494/2014). ASV and NV acknowledge FCT for funding within the FCT Investigator Programme, IF/00803/2012 and IF/00092/2014, respectively. CP-P acknowledges financial support from the Spanish Ministry of Economy and Competitiveness, through grant AGL2014-52395-C2-2-R and the “María de Maeztu” Programme for Units of Excellence in R&D (MDM-2014-0370). PG acknowledges “Comissão de Coordenação e Desenvolvimento Regional do Norte (CCDR-N)/NORTE2020/Portugal 2020” for funding through project DESignBIOtechHealth (ref. Norte-01-0145-FEDER-000024). SH is the recipient of an Australian Research Council Future Fellowship (FT150100398).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

vCPP2319 interacts with metastatic breast cancer extracellular vesicles (EVs) and transposes a human blood-brain barrier model

  • Oliveira, Filipa D.
  • Cavaco, Marco
  • Figueira, Tiago N.
  • Napoleão, Patrícia
  • Valle, Javier
  • Neves, Vera
  • Andreu Martínez, David
  • Castanho, Miguel A.R.B.
Brain metastases (BM) are frequently found in cancer patients and, though their precise incidence is difficult to estimate, there is evidence for a correlation between BM and specific primary cancers, such as lung, breast, and skin (melanoma). Among all these, breast cancer is the most frequently diagnosed among women and, in this case, BM cause a critical reduction of the overall survival (OS), especially in triple negative breast cancer (TNBC) patients. The main challenge of BM treatment is the impermeable nature of the blood-brain barrier (BBB), which shields the central nervous systems (CNS) from chemotherapeutic drugs. Extracellular vesicles (EVs) have been proposed as ideal natural drug carriers and these may exhibit some advantages over synthetic nanoparticles (NPs). In this work, we isolate breast cancer-derived EVs and study their ability to carry vCPP2319, a peptide with dual cell-penetration and anticancer activities. The selective cytotoxicity of anticancer peptide-loaded EVs towards breast cancer cells and their ability to translocate an in vitro BBB model are also addressed. Overall, it was possible to conclude that vCPP2319 naturally interacts with breast cancer-derived EVs, being retained at the surface of these vesicles. Moreover, the results revealed a cytotoxic activity for peptide-loaded EVs similar to that obtained with the peptide alone and the ability of peptide-loaded EVs to translocate an in vitro BBB model, which contrasts with the results obtained with the peptide alone. In conclusion, this work supports the use of EVs in the development of biological drug-delivery systems (DDS) capable of translocating the BBB., FDO and MC acknowledge FCT I.P. for fellowships PD/BD/135046/2017, PD/BD/128281/2017. FCT I.P. is also acknowledged for funding (Projects PTDC/BIA-BQM/5027/2020 and PTDC/BTM-MAT/2472/2021). Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE) is also acknowledged for funding: call H2020-MSCA-RISE-2014, grant agreement 644167, 2015–2019. The project leading to these results have received funding from “la Caixa” Foundation (ID 100010434) and FCT, I.P under the agreement LCF/PR/HP21/52310015. Work at UPF was supported by grant AGL2017-84097-C2-2-R and the “María de Maeztu” Program for Units of Excellence in R&D (MDM-2014-0370) from the Spanish Ministry of Economy and Competitiveness (MINECO).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Decoding the human serum interactome of snake-derived antimicrobial peptide Ctn[15-34]: Toward an explanation for unusually long half-life

  • Pérez-Peinado, Clara, 1991-
  • Defaus, Sira
  • Sans-Comerma, Laura
  • Valle, Javier
  • Andreu Martínez, David
The inherent propensity to enzymatic degradation of most peptides remains a bottleneck in their therapeutic development. Efficient, early screening methods are necessary for in vitro characterization of the molecular events occurring when peptides get in contact with biological fluids such us plasma. Herein we present an affinity purification/MS approach for mapping peptide serum interactors. We have applied this methodology to identify the serum partners of antibiotic peptide Ctn [15-34], aiming to ascertain the molecular interactions underlying its unusually long half-life (~ 12 h) in human serum. From 42 proteins captured in pull-downs with biotinylated Ctn [15-34] as bait, five are of special interest for their transport/binding properties hence alleged peptide arresting potential. The subset contains two members of the albumin superfamily, two apolipoproteins and a globulin. All five share a binding ability for hydrophobic species, and also bind Ctn [15-34], presumably via its C-terminal hydrophobic section, with affinities in the μM range as shown by surface plasmon resonance. Additionally, our functional enrichment reveals several significant immune-related processes suggesting an immunomodulatory role of Ctn [15-34]. Taken together, this study exemplifies how pharmacoproteomics can be used to analyze bioavailability issues and shed light on the serum interactors ultimately conferring protection to Ctn [15-34] against proteolytic events. SIGNIFICANCE: The affinity purification/MS identification methodology reported here can be viewed as a routine pharmacoproteomic approach to investigate the serum interactome of peptide drugs, identifying proteins affecting bioavailability and thus assisting the peptide drug development process. The specific results described here enlighten the serum stability issues of peptide Ctn [15-34] and ratify its promising future as an anti-infective lead., The proteomic analyses were performed at the CRG/UPF Proteomics Unit, which is part of the of Proteored, PRB3 and is supported by grant PT17/0019, of the PE I+D+i 2013-2016, funded by ISCIII and ERDF. This work was supported the Spanish Ministry of Economy and Competitiveness (MINECO) [grant numbers SAF2011-24899 and AGL2014-52395-C2] and by the EU Marie Sklodowska-Curie Research and Innovation Staff Exchange (RISE) program [grant number 644167, 2015-2019]. CP-P acknowledges the MINECO "María de Maeztu" Program for Units of Excellence in R&D (MDM-2014-0370) for a predoctoral fellowship.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

1988-2018: Thirty years of drug smuggling at the nano scale. Challenges and opportunities of cell-penetrating peptides in biomedical research

  • Gallo, María, 1989-
  • Defaus, Sira
  • Andreu Martínez, David
In 1988, two unrelated papers reported the discovery of peptide vectors with innate cell translocation properties, setting the ground for a new area of research that over the years has grown into considerable therapeutic potential. The vectors, named cell-penetrating peptides (CPPs), constitute a now large and diversified family, sharing the extraordinary ability to diffuse unaltered across cell membranes while ferrying diverse associated cargos. Such properties have made CPPs ideal tools for delivery of nucleic acids, proteins and other therapeutic/diagnostic molecules to cells and tissues via covalent conjugation or complexation. This year 2018 marks the 30th anniversary of a peptide research landmark opening new perspectives in drug delivery. Given its vastness, exhaustive coverage of the main features and accomplishments in the CPP field is virtually impossible. Hence this manuscript, after saluting the above 30th jubilee, focuses by necessity on the most recent contributions, providing a comprehensive list of recognized CPPs and their latest-reported applications over the last two years. In addition, it thoroughly reviews three areas of peptide vector research of particular interest to us, namely (i) efficient transport of low-bioavailability drugs into the brain; (ii) CPP-delivered disruptors of G protein-coupled receptor (GPCRs) heteromers related to several disorders, and (iii) CPP-mediated delivery of useful but poorly internalized drugs into parasites., Work supported by the Spanish Ministry of Economy and Competitiveness (MINECO), grants SAF2011-24899 and AGL2014-52395-C2 (to D.A.) and “María de Maeztu” Program for Units of Excellence in R&D (to Pompeu Fabra University). Additional support from the EU Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE) grant 644167, 2015–2019 (D.A. & S.D.).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The mechanism of action of pepR, a viral-derived peptide, against Staphylococcus aureus biofilms

  • Pinto, Sandra N.
  • Dias, Susana A.
  • Cruz, Ana F.
  • Mil-Homens, Dalila
  • Fernandes, Fabio
  • Valle, Javier
  • Andreu Martínez, David
  • Prieto, Manuel
  • Castanho, Miguel A.R.B.
  • Coutinho, Ana
  • Salomé Veiga, Ana
Objectives: To investigate the mechanism of action at the molecular level of pepR, a multifunctional peptide derived from the Dengue virus capsid protein, against Staphylococcus aureus biofilms. Methods: Biofilm mass, metabolic activity and viability were quantified using conventional microbiology techniques, while fluorescence imaging methods, including a real-time calcein release assay, were employed to investigate the kinetics of pepR activity at different biofilm depths. Results: Using flow cytometry-based assays, we showed that pepR is able to prevent staphylococcal biofilm formation due to a fast killing of planktonic bacteria, which in turn resulted from a peptide-induced increase in the permeability of the bacterial membranes. The activity of pepR against pre-formed biofilms was evaluated through the application of a quantitative live/dead confocal laser scanning microscopy (CLSM) assay. The results show that the bactericidal activity of pepR on pre-formed biofilms is dose and depth dependent. A CLSM-based assay of calcein release from biofilm-embedded bacteria was further developed to indirectly assess the diffusion and membrane permeabilization properties of pepR throughout the biofilm. A slower diffusion and delayed activity of the peptide at deeper layers of the biofilm were quantified. Conclusions: Overall, our results show that the activity of pepR on pre-formed biofilms is controlled by its diffusion along the biofilm layers, an effect that can be counteracted by an additional administration of peptide. Our study sheds new light on the antibiofilm mechanism of action of antimicrobial peptides, particularly the importance of their diffusion properties through the biofilm matrix on their activity., This work was supported by the Fundação para a Ciência e a Tecnologia (FCT)/Ministério da Ciência, Tecnologia e Ensino Superior (MCTES) (projects PTDC/QEQ-MED/4412/2014, FAPESP/20107/2014, SAICTPAC/0019/2015, PPBI-POCI-01-0145-FEDER-022122); by the Spanish Ministry of Economy and Competitiveness (MINECO) (grant AGL2014-5239-C2-2R); and by the Marie Skłodowska-Curie Research and Innovation Staff Exchange (grant H2020-MSCA-RISE-2014–644167). We also acknowledge project UID/BIM/50005/2019, funded by FCT/MCTES through Fundos do Orçamento de Estado. S. N. P., S. A. D., A. F. C. and D. M.-H. are the recipients of fellowships from the FCT (SFRH/BPD/92409/2013, PD/BD/114425/2016, PD/BD/136866/2018 and SFRH/BPD/91831/2012, respectively). A. S. V. and F. F. are FCT Researchers (IF/00803/2012 and IF/00386/2015, respectively).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Mechanisms of bacterial membrane permeabilization by crotalicidin (Ctn) and its fragment Ctn(15–34), antimicrobial peptides from rattlesnake venom

  • Pérez-Peinado, Clara, 1991-
  • Almeida Dias, Susana
  • Domingues, Marco M.
  • Benfield, Aurélie H.
  • Miguel Freire, João
  • Rádis-Baptista, Gandhi
  • Gaspar, Diana
  • Castanho, Miguel A.R.B.
  • Craik, David J.
  • Troeira Henriques, Sónia
  • Salomé Veiga, Ana
  • Andreu Martínez, David
Crotalicidin (Ctn), a cathelicidin-related peptide from the venom of a South American rattlesnake, possesses potent antimicrobial, antitumor, and antifungal properties. Previously, we have shown that its C-terminal fragment, Ctn(15-34), retains the antimicrobial and antitumor activities but is less toxic to healthy cells and has improved serum stability. Here, we investigated the mechanisms of action of Ctn and Ctn(15-34) against Gram-negative bacteria. Both peptides were bactericidal, killing ∼90% of Escherichia coli and Pseudomonas aeruginosa cells within 90-120 and 5-30 min, respectively. Studies of ζ potential at the bacterial cell membrane suggested that both peptides accumulate at and neutralize negative charges on the bacterial surface. Flow cytometry experiments confirmed that both peptides permeabilize the bacterial cell membrane but suggested slightly different mechanisms of action. Ctn(15-34) permeabilized the membrane immediately upon addition to the cells, whereas Ctn had a lag phase before inducing membrane damage and exhibited more complex cell-killing activity, probably because of two different modes of membrane permeabilization. Using surface plasmon resonance and leakage assays with model vesicles, we confirmed that Ctn(15-34) binds to and disrupts lipid membranes and also observed that Ctn(15-34) has a preference for vesicles that mimic bacterial or tumor cell membranes. Atomic force microscopy visualized the effect of these peptides on bacterial cells, and confocal microscopy confirmed their localization on the bacterial surface. Our studies shed light onto the antimicrobial mechanisms of Ctn and Ctn(15-34), suggesting Ctn(15-34) as a promising lead for development as an antibacterial/antitumor agent., This work was supported by Spanish Ministry of Economy and Competitiveness (MINECO) Grants SAF2011-24899 and AGL2014-52395-C2, by Fundação para a Ciência e a Tecnologia (FCT, Portugal) Grants PTDC/QEQ-MED/4412/2014, and by EU Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE) program Grant 644167, 2015–2019. The authors declare that they have no conflicts of interest with the contents of this article.